US FDA’s Latest Review Of Stealth’s Elamipretide Will Move With Speed

 
• By Kevin Grogan
  
Racetrack
US FDA expects to make a regulatory decision on Stealth's elamipretide NDA resubmission in just over a month. • Source: Shutterstock

More from Product Reviews

More from Pink Sheet